| Alex Samuel Carcamo, MD | |
|
100 Kahelu Ave Ste 226, Mililani, HI 96789-3962 | |
| (808) 621-1000 | |
| (808) 627-6000 |
| Full Name | Alex Samuel Carcamo |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 24 Years |
| Location | 100 Kahelu Ave Ste 226, Mililani, Hawaii |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1992759211 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207NS0135X | Dermatology - Procedural Dermatology | A87398 (California) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Complete Dermatology | 1759510316 | 7 |
News Archive
Many parents, potential players and medical providers are increasingly wary of youth contact sports participation. The concern over the potential short- and long-term effects of head impacts experienced by youth football players has likely driven decreasing participation, according to a group of researchers.
Sometimes the whole is greater than the sum of its parts. Researchers at Cold Spring Harbor Laboratory have discovered that two cell mutations, already harmful alone, enhance one another's effects, contributing to the development of the deadly blood cancer acute myeloid leukemia (AML).
News outlets offer more analysis of Wednesday night's debate, including examinations of plans and proposals about Medicare and pre-existing conditions.
The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today publically congratulated its sponsor partner Cosmo Pharmaceuticals S.p.A. who last week announced positive top-line results from their second pivotal Phase III clinical study which was conducted in the EU utilizing DATATRAK's unified eClinical product suite and services team to evaluate the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate ulcerative colitis.
› Verified 9 days ago
| Entity Name | Complete Dermatology |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467794842 PECOS PAC ID: 1759510316 Enrollment ID: O20140131001692 |
News Archive
Many parents, potential players and medical providers are increasingly wary of youth contact sports participation. The concern over the potential short- and long-term effects of head impacts experienced by youth football players has likely driven decreasing participation, according to a group of researchers.
Sometimes the whole is greater than the sum of its parts. Researchers at Cold Spring Harbor Laboratory have discovered that two cell mutations, already harmful alone, enhance one another's effects, contributing to the development of the deadly blood cancer acute myeloid leukemia (AML).
News outlets offer more analysis of Wednesday night's debate, including examinations of plans and proposals about Medicare and pre-existing conditions.
The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today publically congratulated its sponsor partner Cosmo Pharmaceuticals S.p.A. who last week announced positive top-line results from their second pivotal Phase III clinical study which was conducted in the EU utilizing DATATRAK's unified eClinical product suite and services team to evaluate the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate ulcerative colitis.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex Samuel Carcamo, MD 100 Kahelu Ave Ste 226, Mililani, HI 96789-3962 Ph: (808) 772-2837 | Alex Samuel Carcamo, MD 100 Kahelu Ave Ste 226, Mililani, HI 96789-3962 Ph: (808) 621-1000 |
News Archive
Many parents, potential players and medical providers are increasingly wary of youth contact sports participation. The concern over the potential short- and long-term effects of head impacts experienced by youth football players has likely driven decreasing participation, according to a group of researchers.
Sometimes the whole is greater than the sum of its parts. Researchers at Cold Spring Harbor Laboratory have discovered that two cell mutations, already harmful alone, enhance one another's effects, contributing to the development of the deadly blood cancer acute myeloid leukemia (AML).
News outlets offer more analysis of Wednesday night's debate, including examinations of plans and proposals about Medicare and pre-existing conditions.
The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.
DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today publically congratulated its sponsor partner Cosmo Pharmaceuticals S.p.A. who last week announced positive top-line results from their second pivotal Phase III clinical study which was conducted in the EU utilizing DATATRAK's unified eClinical product suite and services team to evaluate the safety and efficacy of budesonide MMX for the induction of remission of mild or moderate ulcerative colitis.
› Verified 9 days ago